题名 | Tubuloside B, isolated from Cistanche tubulosa, a promising agent against M1 macrophage activation via synergistically targeting Mob1 and ERK1/2 |
作者 | |
通讯作者 | Ge,Lanlan |
发表日期 | 2022-09-01
|
DOI | |
发表期刊 | |
ISSN | 0753-3322
|
EISSN | 1950-6007
|
卷号 | 153 |
摘要 | Targeting macrophage M1 polarization is a promising strategy with fewer detrimental effects in COVID-19 curation. Phenylethanoid glycosides (PhGs) of Cistanche tubulosa are a botanical drug to possess various anti-inflammation-related functions, such as immunomodulating, hepatoprotective or neuroprotective functions, whereas their anti-inflammatory activity is rarely understood. A search into their anti-inflammatory characteristics led to the isolation of 49 PhGs along with 15 new PhGs. Their inhibitory effects against M1 polarization induced by LPS plus IFN-γ were explored in RAW264.7 macrophages. Of these PhGs, tubuloside B (Tub B) exerted substantial NO scavenging effect both in chemical- and cell-based assays, and it inhibited massive production of cytokines and chemokines. Tub B decreased ERK1/2 phosphorylation via direct binding and inhibited the MAPK signaling pathway. Tub B also directly binded to Mob1 protein, thereby increased the stability and level of Mob1 protein by inhibiting ubiquitinated degradation. Mob1 was pivotal for the anti-inflammatory activity of Tub B, and it acted independently of the canonical Hippo-YAP pathway. Moreover, ERK1/2 and Mob1 also had a synergic effect on modulating the inflammatory response. Finally, these effects of Tub B were verified in mice with LPS-induced systemic inflammatory response syndrome. Taken together, these results indicated that Tub B acted as a promising agent against M1 macrophage activation by synergistically targeting ERK1/2 and Mob1, and that it may potentially be a drug candidate to prevent/treat inflammatory diseases, especially in COVID-19. |
关键词 | |
相关链接 | [Scopus记录] |
收录类别 | |
语种 | 英语
|
学校署名 | 第一
; 通讯
|
资助项目 | Natural Science Foundation of Guangdong Province[2017A030313659];China Postdoctoral Science Foundation[2019M653300];Natural Science Foundation of Guangdong Province[2021A1515110841];National Natural Science Foundation of China[81503221];National Natural Science Foundation of China[81903760];National Natural Science Foundation of China[81903914];Science and Technology Planning Project of Shenzhen Municipality[JCYJ20160427183814675];Science and Technology Planning Project of Shenzhen Municipality[JCYJ20170307095556333];Science and Technology Planning Project of Shenzhen Municipality[JCYJ20170307100726777];Science and Technology Planning Project of Shenzhen Municipality[JCYJ20170413093108233];Science and Technology Planning Project of Shenzhen Municipality[JCYJ20190806151816859];Science and Technology Planning Project of Shenzhen Municipality[JCYJ20190806153401647];Science and Technology Planning Project of Shenzhen Municipality[JCYJ20210324113003007];
|
WOS研究方向 | Research & Experimental Medicine
; Pharmacology & Pharmacy
|
WOS类目 | Medicine, Research & Experimental
; Pharmacology & Pharmacy
|
WOS记录号 | WOS:000918968700003
|
出版者 | |
Scopus记录号 | 2-s2.0-85134594708
|
来源库 | Scopus
|
引用统计 |
被引频次[WOS]:5
|
成果类型 | 期刊论文 |
条目标识符 | http://sustech.caswiz.com/handle/2SGJ60CL/359539 |
专题 | 南方科技大学第一附属医院 |
作者单位 | 1.Center Lab of Longhua Branch and Department of Infectious Disease,Shenzhen People's Hospital (The Second Clinical Medical College,Jinan University,Southern University of Science and Technology),Shenzhen,Guangdong,518020,China 2.Department of Pathology (Longhua Branch),Shenzhen People's Hospital (The Second Clinical Medical College,Jinan University,Southern University of Science and Technology),Shenzhen,Guangdong,518020,China 3.College of Life Science,Jiangsu Normal University,Xuzhou,Jiangsu Province,221116,China 4.Guangdong Provincial Key Laboratory of Regional Immunity and Diseases,Medicine School of Shenzhen University,Shenzhen,Guangdong Province,518037,China |
第一作者单位 | 南方科技大学第一附属医院 |
通讯作者单位 | 南方科技大学第一附属医院 |
第一作者的第一单位 | 南方科技大学第一附属医院 |
推荐引用方式 GB/T 7714 |
Xiao,Lingyun,Yao,Jie,Miao,Yuyang,et al. Tubuloside B, isolated from Cistanche tubulosa, a promising agent against M1 macrophage activation via synergistically targeting Mob1 and ERK1/2[J]. BIOMEDICINE & PHARMACOTHERAPY,2022,153.
|
APA |
Xiao,Lingyun.,Yao,Jie.,Miao,Yuyang.,Ou,Baoru.,Wang,Jie.,...&Zeng,Xiaobin.(2022).Tubuloside B, isolated from Cistanche tubulosa, a promising agent against M1 macrophage activation via synergistically targeting Mob1 and ERK1/2.BIOMEDICINE & PHARMACOTHERAPY,153.
|
MLA |
Xiao,Lingyun,et al."Tubuloside B, isolated from Cistanche tubulosa, a promising agent against M1 macrophage activation via synergistically targeting Mob1 and ERK1/2".BIOMEDICINE & PHARMACOTHERAPY 153(2022).
|
条目包含的文件 | 条目无相关文件。 |
|
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论